Reven Pharmaceuticals, Inc.
๐บ๐ธUnited States
Tolerability and Efficacy of RJX in Patients With COVID-19
Phase 1
- Conditions
- COVID-19Acute Respiratory Distress SyndromeSARS-CoV-2Hypoxemia
- Interventions
- Drug: Rejuveinix (RJX) Active ComparatorDrug: Placebo Comparator
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Reven Pharmaceuticals, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT04708340
- Locations
- ๐บ๐ธ
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States
๐บ๐ธMemorial Hermann Southeast Hospital, Houston, Texas, United States
๐บ๐ธChristus Santa Rosa Hospital, New Braunfels, Texas, United States
A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Reven Pharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT03680105
- Locations
- ๐บ๐ธ
ICON Early Phase Services, San Antonio, Texas, United States
Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
Phase 1
- Conditions
- Critical Limb IschemiaPeripheral Arterial Disease
- Interventions
- Drug: Rejuveinix Low DoseDrug: Rejuveinix High Dose
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Reven Pharmaceuticals, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT03041259
ยฉ Copyright 2025. All Rights Reserved by MedPath